Taysha Gene Therapies
TSHA
150 hedge funds and large institutions have $595M invested in Taysha Gene Therapies in 2025 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 48 increasing their positions, 34 reducing their positions, and 20 closing their positions.
889% more call options, than puts
Call options by funds: $465K | Put options by funds: $47K
157% more capital invested
Capital invested by funds: $232M → $595M (+$363M)
120% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 20
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
41% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 34
18% more funds holding
Funds holding: 127 → 150 (+23)
13.08% more ownership
Funds ownership: 81.39% → 94.47% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$27.6M |
| 2 |
Goldman Sachs
New York
|
+$26.6M |
| 3 |
JFG
Jefferies Financial Group
New York
|
+$21.9M |
| 4 |
RI
RTW Investments
New York
|
+$13.5M |
| 5 |
DM
Deerfield Management
New York
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.7M |
| 2 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$1.48M |
| 3 |
SCM
Superstring Capital Management
New York
|
-$1.05M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$726K |
| 5 |
BlackRock
New York
|
-$620K |
TSHA Hedge Fund Activity: Q2 2025 in Review
150 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q2 2025, worth a combined $595M — up 157% from $232M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new TSHA positions and 20 closed out — a net gain of 24 holders — while 48 added to existing stakes and 34 trimmed.
The largest buyer was RA Capital Management, adding an estimated $27.6M. The largest seller was JP Morgan Chase, cutting an estimated $1.7M.
- 150 institutional investors held Taysha Gene Therapies (TSHA) as of Q2 2025, up from 127 in Q1 2025.
- Funds reported $595M of Taysha Gene Therapies stock for Q2 2025, up 157% quarter-over-quarter.
- 44 funds opened new Taysha Gene Therapies positions in Q2 2025 and 20 closed out, a net change of +24 holders.
- The largest Taysha Gene Therapies buyer in Q2 2025 was RA Capital Management, an estimated $27.6M added.
- The largest Taysha Gene Therapies seller in Q2 2025 was JP Morgan Chase, an estimated $1.7M sold.
Based on aggregated 13F filings for Q2 2025.